CDC: 1 in 3 teen girls got cervical cancer vaccine

Sep 17, 2009 By MIKE STOBBE , AP Medical Writer

(AP) -- A new government report shows one in three teenage girls have rolled up their sleeves for a relatively new vaccine against cervical cancer, but vaccination rates vary dramatically between states.

The highest rates were in Rhode Island and New Hampshire, where more than half of girls ages 13 through 17 got at least one dose of three-shot vaccination. The lowest rates were in Mississippi, Georgia and South Carolina.

The federal report is the first to give state-by-state rates for the Gardasil vaccine that targets the sexually transmitted . The report was released Thursday by the .

---

On the Net:

CDC report: http://www.cdc.gov/mmwr

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Opioid users breathe easier with novel drug to treat respiratory depression

add to favorites email to friend print save as pdf

Related Stories

N.H. finds voluntary vaccination works

May 13, 2007

New Hampshire says it has a winning formula for getting teenage girls vaccinated against a virus linked to cervical cancer -- make the shot voluntary.

CDC, states: US swine flu cases jump to 68

Apr 28, 2009

(AP) -- The number of confirmed swine flu cases in the United States has jumped to 64, federal officials said Tuesday, and states reported at least four more.

Recommended for you

Boxed warnings are common in novel therapeutics

20 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

21 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

22 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0